Linked Life Data

10066072

Source:http://linkedlifedata.com/resource/pubmed/id/10066072

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1-3
pubmed:dateCreated
1999-4-29
pubmed:abstractText
c-erbB2 is a proto-oncogene that encodes the trans-membrane protein p185. This protein shares considerable sequence and structure homology with members of the epidermal growth factor receptor family and it is believed to cooperate with these receptors in the signal transduction process in order to control cell proliferation. Overexpression of c-erbB2, with or without gene amplification, is frequently found in breast cancer, and a body of evidence suggests it is implicated in the development of resistance to the antiestrogen tamoxifen. Scientific evidence strongly supports a correlation between c-erbB2 overexpression and lack of efficacy of tamoxifen in both advanced and adjuvant settings. However, given the important therapeutic repercussion of this topic, further studies are required before c-erbB2 evaluation can be routinely used to select patients who are likely to benefit from tamoxifen administration.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0167-6806
pubmed:author
pubmed:issnType
Print
pubmed:volume
52
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
55-64
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed:year
1998
pubmed:articleTitle
c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients.
pubmed:affiliation
Cattedra di Oncologia Medica, Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica, Università Federico II, Napoli, Italy.
pubmed:publicationType
Journal Article, Review